Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00861575 · ClinicalTrials.gov registry record

Cardiogenomics Registry

A clinical trial of Cardiovascular Disease, sponsored by Piedmont Healthcare.

Completed
Registry status
2,601
Enrollment target
1
Study location

NCT00861575 is a study of Cardiovascular Disease that has completed, run by Piedmont Healthcare. The registered enrollment target is 2,601 participants, roughly in line with the 2,694-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00861575, a study of Cardiovascular Disease, has completed, sponsored by Piedmont Healthcare.

COMPLETED
Registry status
2,601 participants
Enrollment target
1
Study location

Study Summary

This is a continuous blood banking study that will archive plasma and blood permitting DNA and plasma analysis at a future date. Subjects are recruited at the time of a clinically required procedure and blood samples are collected and banked and used for future research. The main purpose of this study is to investigate the interaction of multiple phenotypes and genotypes and their impact on cardiovascular disease events and measures of atherosclerosis progression.

Conditions Studied

Study Locations (1)

Georgia

  • Piedmont Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 2,601 participants
Start Date 2006-02
Est. Completion 2012-02

Sponsor

Piedmont Healthcare

13 total trials

What the Registry Record Tells You About NCT00861575

The ClinicalTrials.gov registry entry for NCT00861575 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,601 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 2,694-participant average among 136 other Cardiovascular Disease trials with a reported enrollment target. The listed sponsor is Piedmont Healthcare, which has 13 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 0 interventions.

NCT00861575 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.

Frequently Asked Questions

What is clinical trial NCT00861575 about?

NCT00861575 is a clinical study titled "Cardiogenomics Registry". This is a continuous blood banking study that will archive plasma and blood permitting DNA and plasma analysis at a future date. Subjects are recruited at the time of a clinically required procedure and blood samples are collected and banked and used for future research. The main purpose of this stu...

What is the current status of trial NCT00861575?

This trial is currently completed. The enrollment target is 2,601 participants. The study started on 2006-02. Estimated completion is 2012-02.

What conditions does trial NCT00861575 study?

This clinical trial studies the following conditions: Cardiovascular Disease.

Who is sponsoring clinical trial NCT00861575?

This trial is sponsored by Piedmont Healthcare, which has 13 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00861575 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.